216 related articles for article (PubMed ID: 30136888)
1. Effect of Mucoadhesive Polymeric Formulation on Corneal Permeation of Fluoroquinolones.
Gade SK; Shivshetty N; Sharma N; Bhatnagar S; Garg P; Venuganti VVK
J Ocul Pharmacol Ther; 2018 Oct; 34(8):570-578. PubMed ID: 30136888
[TBL] [Abstract][Full Text] [Related]
2. Corneal delivery of besifloxacin using rapidly dissolving polymeric microneedles.
Bhatnagar S; Saju A; Cheerla KD; Gade SK; Garg P; Venuganti VVK
Drug Deliv Transl Res; 2018 Jun; 8(3):473-483. PubMed ID: 29288357
[TBL] [Abstract][Full Text] [Related]
3. Preparation and evaluation of novel chitosan: gelrite ocular system containing besifloxacin for topical treatment of bacterial conjunctivitis: scintigraphy, ocular irritation and retention assessment.
Imam SS; Bukhari SNA; Ali A
Artif Cells Nanomed Biotechnol; 2018 Aug; 46(5):959-967. PubMed ID: 28708424
[TBL] [Abstract][Full Text] [Related]
4. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
Chang MH; Fung HB
Clin Ther; 2010 Mar; 32(3):454-71. PubMed ID: 20399984
[TBL] [Abstract][Full Text] [Related]
5. Besifloxacin ophthalmic suspension 0.6%.
Carter NJ; Scott LJ
Drugs; 2010; 70(1):83-97. PubMed ID: 20030427
[TBL] [Abstract][Full Text] [Related]
6. Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates.
Sanfilippo CM; Allaire CM; DeCory HH
Drugs R D; 2017 Mar; 17(1):167-175. PubMed ID: 28078599
[TBL] [Abstract][Full Text] [Related]
7. Besifloxacin ophthalmic suspension for bacterial conjunctivitis.
Nafziger AN; Bertino JS
Drugs Today (Barc); 2009 Aug; 45(8):577-88. PubMed ID: 19927224
[TBL] [Abstract][Full Text] [Related]
8. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans.
Proksch JW; Granvil CP; Siou-Mermet R; Comstock TL; Paterno MR; Ward KW
J Ocul Pharmacol Ther; 2009 Aug; 25(4):335-44. PubMed ID: 19492955
[TBL] [Abstract][Full Text] [Related]
9. Formulation and optimization of levofloxacin loaded chitosan nanoparticle for ocular delivery: In-vitro characterization, ocular tolerance and antibacterial activity.
Ameeduzzafar ; Imam SS; Abbas Bukhari SN; Ahmad J; Ali A
Int J Biol Macromol; 2018 Mar; 108():650-659. PubMed ID: 29199125
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
[TBL] [Abstract][Full Text] [Related]
11. Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.
Bertino JS; Zhang JZ
Expert Opin Pharmacother; 2009 Oct; 10(15):2545-54. PubMed ID: 19743941
[TBL] [Abstract][Full Text] [Related]
12. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL
Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
Comstock TL; Paterno MR; Usner DW; Pichichero ME
Paediatr Drugs; 2010 Apr; 12(2):105-12. PubMed ID: 20218747
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.
Sanders ME; Norcross EW; Moore QC; Shafiee A; Marquart ME
Cornea; 2009 Oct; 28(9):1055-60. PubMed ID: 19724203
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis.
Sanders ME; Moore QC; Norcross EW; Shafiee A; Marquart ME
J Ocul Pharmacol Ther; 2010 Apr; 26(2):193-8. PubMed ID: 20334537
[TBL] [Abstract][Full Text] [Related]
16. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
Proksch JW; Ward KW
J Ocul Pharmacol Ther; 2010 Oct; 26(5):449-58. PubMed ID: 20874668
[TBL] [Abstract][Full Text] [Related]
17. The role of besifloxacin in the treatment of bacterial conjunctivitis.
Mahvan TD; Hornecker JR; Buckley WA; Clark S
Ann Pharmacother; 2014 May; 48(5):616-25. PubMed ID: 24566460
[TBL] [Abstract][Full Text] [Related]
18. Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.
Sanders ME; Moore QC; Norcross EW; Sanfilippo CM; Hesje CK; Shafiee A; Marquart ME
Cornea; 2011 Jan; 30(1):83-90. PubMed ID: 20847656
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
[TBL] [Abstract][Full Text] [Related]
20. Comparative intraocular penetration of 4 fluoroquinolones after topical instillation.
Chung JL; Lim EH; Song SW; Kim BY; Lee JH; Mah FS; Seo KY
Cornea; 2013 Jul; 32(7):1046-51. PubMed ID: 23615274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
